Metabolic Disorders News and Research

RSS

Alizé Pharma presents clinical results from the AZP-531 program at the ADA 75th Scientific Sessions

Detailed data will be presented from the two Phase I trials conducted in 76 healthy volunteers and overweight or obese subjects...

26 May 2015

Splicing pattern of obesity, type 2 diabetes genes may contribute to pathophysiology of obesity

Alternative splicing of obesity and type 2 diabetes related genes may contribute to the pathophysiology of obesity, according to research from the University of Eastern Finland. Obesity leads to changes in the splicing pattern of metabolically relevant genes such as TCF7L2 and INSR, resulting in impaired insulin action.

22 May 2015

Shiftworkers more likely to develop metabolic disorders

Shiftwork is an occupational health risk of growing significance because it is becoming more common and because of its potential influence on health outcomes, possibly increasing health differences between workers of higher vs lower socioeconomic status.

18 May 2015

Obese people at greater risk of developing cancer

Cancer is more likely to develop in people who are very overweight (obese), because surplus body fat interferes with various hormone cycles and with glucose and fat metabolism. On the occasion of European Obesity Day this coming Saturday (16 May), metabolic expert Alexandra Kautzky-Willer, Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital, draws attention to the fact that, even in Austria, more and more people are suffering from obesity.

12 May 2015

Scripps Florida scientists uncover surprising new details of potential alzheimer’s treatment

The new study points to promising new directions using a known therapeutic strategy for Alzheimer’s disease—a disorder that will affect nearly 14 million Americans by 2050, according to the Alzheimer’s Association...

29 Apr 2015

New TSRI study points to promising new therapeutic target for Alzheimer's disease

Taking a new approach, scientists from the Florida campus of The Scripps Research Institute (TSRI) have uncovered some surprising details of a group of compounds that have shown significant potential in stimulating the growth of brain cells and memory restoration in animal models that mimic Alzheimer's disease.

29 Apr 2015

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 (“miR-103/107”) for the treatment of Non Alcoholic Steatohepatitis (“NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies’ strategic alliance to discover, develop and commercialize microRNA therapeutics.

9 Apr 2015

New study analyses physical, psychological consequences of bariatric surgery

Bariatric surgery, or reduction of gastric capacity, is one of the longer lasting options to achieve considerable weight loss in obese people. A Spanish researcher has participated in a study that confirms that the effects of this relatively complex medical surgery are not only physical, but also psychological.

8 Apr 2015

Ablative Solutions named recipient of CRT's Top Cardiovascular Innovation Award

Ablative Solutions, Inc., a venture-backed, privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it was the recipient of a "Top Cardiovascular Innovation Award" from Cardiovascular Research Technologies for the Peregrine System.

12 Mar 2015

Intestinal bacteria can cause type 2 diabetes in African American men

African American men at elevated risk for developing type 2 diabetes may have fewer beneficial and more harmful intestinal bacteria, according to research presented by University of Illinois at Chicago endocrinologist Dr. Irina Ciubotaru at the ENDO 2015 meeting in San Diego.

9 Mar 2015

Alizé Pharma announces launch of AZP-531 Phase II trial in patients with Prader-Willi syndrome

Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.

3 Mar 2015

Moderate drinking of red grape wine helps overweight people burn fat better

Drinking red grape juice or wine - in moderation - could improve the health of overweight people by helping them burn fat better, according to a new study coauthored by an Oregon State University researcher.

9 Feb 2015

Scientists reveal genetic links to metabolic disorders

For at least 40 years, scientists who study how the body metabolizes sugar have accepted one point: there are four enzymes that kick-start the body's process of getting energy from food.

5 Feb 2015

BellBrook Labs announces launch of new Transcreener UDP TR-FRET Assay

BellBrook Labs, a leader in high throughput screening assays for drug discovery, announced the launch of a TR-FRET (time resolved Forster resonance energy transfer) version of the company's Transcreener UDP Assay, a high throughput screening assay for glycosyltransferases and other UDP-producing enzymes.

15 Jan 2015

U-M researchers identify how amlexanox drug improves metabolism of sugar

Researchers at the University of Michigan have identified how a promising drug in clinical trials for the treatment of obesity and related metabolic disorders improves the metabolism of sugar by generating a new signal between fat cells and the liver.

13 Jan 2015

Alizé Pharma completes two Phase I clinical trials of AZP-531 in healthy volunteers, obese subjects

Alizé Pharma SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, announces today the completion of two Phase I clinical trials with its unacylated ghrelin analog AZP-531 in 76 healthy volunteers and overweight or obese subjects.

10 Dec 2014

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, today announces that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties.

4 Dec 2014

Component of Glycyrrhiza uralensis plant may thwart development of metabolic disorders

New research published in the December 2014 issue of the Journal of Leukocyte Biology, shows that a component found in in the plant, Glycyrrhiza uralensis, may inhibit the development of metabolic disorders by stopping the activation of NLRP3, a protein involved in the disease process.

2 Dec 2014

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today presented detailed results from HARMONIZE (ZS004) at the late-breaking Clinical Science Special Reports Session of the American Heart Association Scientific Sessions.

18 Nov 2014

Research finding points to potential new treatment for metabolic disorders

Researchers at the University of Michigan have discovered how a previously unknown hormone serves as a messenger from fat cells to the liver and are investigating the potential of developing a new treatment for metabolic disorders.

17 Nov 2014